Loading
Cutaneous Lymphoproliferative Disorders Research · Journal article
Materials Today Bio · September 1, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study demonstrating that a chondroitin sulfate microneedle platform co-delivering CRISPR/Cas9 ribonucleoprotein and doxorubicin achieves high gene editing and tumor cell death in vitro and significant tumor reduction in mouse melanoma xenografts. The work is mechanistically interesting but remains far from clinical translation; no human efficacy, safety, or comparative data are provided.
Uncontrolled in vitro and in vivo preclinical study. Melanoma cell lines (unspecified) in vitro; C57BL/6 mice with implanted melanoma tumors in vivo. No human subjects.. Intervention: Chondroitin sulfate-based microneedles delivering CRISPR/Cas9 ribonucleoprotein (RNP) targeting YB-1 gene combined with doxorubicin (DOX) via engineered nanoparticles (CNPs).. Compared with: Untreated control in vivo; no active comparator or standard-of-care arm described..
In vitro dual-drug delivery rate of 74.4% with 65.32% gene editing efficiency achieved by CNPs. CNPs@DOX@RNP reduced tumor cell viability to 3.51% in vitro. In vivo tumor weight reduction of 92.56% relative to untreated control in C57BL/6 melanoma models.
Off-target toxicity mentioned qualitatively but quantitative safety metrics (organ weights, histology, biomarkers) not provided. Biocompatibility assays confirmed safety with minimal organ damage.
This work suggests a potential future direction for combining CRISPR gene editing with chemotherapy via transdermal delivery, but is strictly experimental. No clinician should consider this as evidence for therapeutic use; further preclinical optimization, toxicology work, and eventually first-in-human trials would be required.
Early-stage preclinical work demonstrating proof-of-concept in cell and animal models; no human data, surrogate endpoints only, and no direct clinical comparator.
As stated by the source record.
Quoted from the source exactly as published.
This work suggests a potential future direction for combining CRISPR gene editing with chemotherapy via transdermal delivery, but is strictly experimental. No clinician should consider this as evidence for therapeutic use; further preclinical optimization, toxicology work, and eventually first-in-human trials would be required.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Melanoma's aggressiveness and therapeutic resistance highlight the need for innovative strategies. This study developed a CRISPR/Cas9 ribonucleoprotein (RNP) system targeting the oncogenic YB-1 gene, combined with doxorubicin (DOX), delivered by chondroitin sulfate (CS)-based microneedles (MN) incorporating designed nanoparticles (CNPs). YB-1, a critical oncogene driving melanoma progression, metastasis, and drug resistance, was targeted to enhance therapy efficacy. In vitro experiments demonstrated that CNPs enhanced cellular uptake efficiency, achieving a dual-drug delivery rate of 74.4% and mediating 65.32% gene editing efficiency. The application of CNPs@DOX@RNP reduced tumor cell viability to just 3.51%, while simultaneously lowering off-target toxicity. In vivo C57BL/6 melanoma models showed significant tumor growth inhibition, increased apoptosis, and suppressed proliferation/angiogenesis. Following treatment with CNPs@DOX@RNP/MN, tumor weight exhibited a 92.56% reduction relative to the untreated control. Biocompatibility assays confirmed safety with minimal organ damage. This MN platform offers a synergistic, safe, and effective strategy for combined YB-1 gene editing and chemotherapy, addressing melanoma's therapeutic challenges.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.